Article Information
History
- April 23, 2021.
Article Versions
- You are currently viewing Version 1 of this article (April 23, 2021 - 11:19).
- Version 2 (July 29, 2021 - 00:50).
- Version 3 (July 30, 2021 - 00:31).
- Version 4 (November 17, 2021 - 02:53).
- Version 5 (November 18, 2021 - 02:50).
- Version 6 (November 22, 2021 - 03:03).
- View Version 7, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Satoshi Imanishi1,#,
- Lijuan Huang1,#,
- Shoko Itakura2,
- Masamichi Ishizaka1,
- Megumi Tsukamoto1,
- Megumi Saito1,
- Yoichi Iwasaki1,
- Tomohiro Yamaguchi1 and
- Etsuko Miyamoto-Sato1,*
- 1Laboratory of Miyamoto-Sato Molecular Medical Sciences, Research Institute for Science & Technology, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-0022, Japan
- 2Graduate School of Biological Sciences, Tokyo University of Science, 2641 Yamazaki, Noda, Chiba 278-0022, Japan
- ↵*Correspondence: nekoneko{at}rs.tus.ac.jp
↵# These authors contributed equally to this work.
Posted April 23, 2021.
In vivo KRAS G12D/V Degradation Mediated by CANDDY Using a Modified Proteasome Inhibitor
